Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine + ramucirumab in previously treated CEACAM5-positive advanced gastric or GEJ adenocarcinoma
jRCT2011210035Completed
- Sponsor
- Sanofi
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of tusamitamab ravtansine and ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sanofi. Primary endpoints: Incidence of study drug-related dose-limiting toxicities and Objective response rate. Started Nov 2021; status: completed.
02
Drugs
tusamitamab ravtansineramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2011210035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210035.